215 related articles for article (PubMed ID: 38656686)
1. Molecular Heterogeneity in Leiomyosarcoma and Implications for Personalised Medicine.
Arfan S; Thway K; Jones RL; Huang PH
Curr Treat Options Oncol; 2024 May; 25(5):644-658. PubMed ID: 38656686
[TBL] [Abstract][Full Text] [Related]
2. ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour.
Edris B; Espinosa I; Mühlenberg T; Mikels A; Lee CH; Steigen SE; Zhu S; Montgomery KD; Lazar AJ; Lev D; Fletcher JA; Beck AH; West RB; Nusse R; van de Rijn M
J Pathol; 2012 Jun; 227(2):223-33. PubMed ID: 22294416
[TBL] [Abstract][Full Text] [Related]
3. Leiomyosarcoma: Prognostic outline of a rare head and neck malignancy.
Saluja TS; Iyer J; Singh SK
Oral Oncol; 2019 Aug; 95():100-105. PubMed ID: 31345375
[TBL] [Abstract][Full Text] [Related]
4.
Seligson ND; Kautto EA; Passen EN; Stets C; Toland AE; Millis SZ; Meyer CF; Hays JL; Chen JL
Oncologist; 2019 Jul; 24(7):973-979. PubMed ID: 30541756
[TBL] [Abstract][Full Text] [Related]
5. Identification of a Novel MAN1A1-ROS1 Fusion Gene Through mRNA-based Screening for Tyrosine Kinase Gene Aberrations in a Patient with Leiomyosarcoma.
Suehara Y; Kohsaka S; Hayashi T; Akaike K; Kurisaki-Arakawa A; Sato S; Kobayashi E; Mizuno S; Ueno T; Morii T; Okuma T; Kurihara T; Hasegawa N; Sano K; Sasa K; Okubo T; Kim Y; Mano H; Saito T
Clin Orthop Relat Res; 2021 Apr; 479(4):838-852. PubMed ID: 33196586
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling in leiomyosarcomas and undifferentiated pleomorphic sarcomas: SRC as a new diagnostic marker.
Villacis RA; Silveira SM; Barros-Filho MC; Marchi FA; Domingues MA; Scapulatempo-Neto C; Aguiar S; Lopes A; Cunha IW; Rogatto SR
PLoS One; 2014; 9(7):e102281. PubMed ID: 25028927
[TBL] [Abstract][Full Text] [Related]
7. Uterine leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome.
Cui RR; Wright JD; Hou JY
BJOG; 2017 Jun; 124(7):1028-1037. PubMed ID: 28128524
[TBL] [Abstract][Full Text] [Related]
8. Expression of subtype-specific group 1 leiomyosarcoma markers in a wide variety of sarcomas by gene expression analysis and immunohistochemistry.
Mills AM; Beck AH; Montgomery KD; Zhu SX; Espinosa I; Lee CH; Subramanian S; Fletcher CD; van de Rijn M; West RB
Am J Surg Pathol; 2011 Apr; 35(4):583-9. PubMed ID: 21412072
[TBL] [Abstract][Full Text] [Related]
9. Leiomyosarcoma: Does Location of Primary Help to Determine the Best Systemic Therapy Options?
Novotny JP; George S
Curr Treat Options Oncol; 2021 Sep; 22(11):99. PubMed ID: 34524549
[TBL] [Abstract][Full Text] [Related]
10. Integrated genomic and transcriptomic analysis revealed mutation patterns of de-differentiated liposarcoma and leiomyosarcoma.
Liu W; Tong H; Zhang C; Zhuang R; Guo H; Lv C; Yang H; Lin Q; Guo X; Wang Z; Wang Y; Shen F; Wang S; Dai C; Wang G; Liu J; Lu W; Zhang Y; Zhou Y
BMC Cancer; 2020 Oct; 20(1):1035. PubMed ID: 33115433
[TBL] [Abstract][Full Text] [Related]
11. What Clinical Trials Are Needed for Treatment of Leiomyosarcoma?
Kasper B; D'Ambrosio L; Davis EJ; Ingham M; Broto JM; Trent JC; van Houdt WJ; Van Tine BA
Curr Treat Options Oncol; 2022 Mar; 23(3):439-449. PubMed ID: 35275323
[TBL] [Abstract][Full Text] [Related]
12. Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling.
Beck AH; Lee CH; Witten DM; Gleason BC; Edris B; Espinosa I; Zhu S; Li R; Montgomery KD; Marinelli RJ; Tibshirani R; Hastie T; Jablons DM; Rubin BP; Fletcher CD; West RB; van de Rijn M
Oncogene; 2010 Feb; 29(6):845-54. PubMed ID: 19901961
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis, prognosis, and management of leiomyosarcoma: recognition of anatomic variants.
Bathan AJ; Constantinidou A; Pollack SM; Jones RL
Curr Opin Oncol; 2013 Jul; 25(4):384-9. PubMed ID: 23635801
[TBL] [Abstract][Full Text] [Related]
14. Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma.
Przybyl J; Chabon JJ; Spans L; Ganjoo KN; Vennam S; Newman AM; Forgó E; Varma S; Zhu S; Debiec-Rychter M; Alizadeh AA; Diehn M; van de Rijn M
Clin Cancer Res; 2018 Jun; 24(11):2688-2699. PubMed ID: 29463554
[No Abstract] [Full Text] [Related]
15. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
16. Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma.
Dermawan JK; Chiang S; Singer S; Jadeja B; Hensley ML; Tap WD; Movva S; Maki RG; Antonescu CR
Clin Cancer Res; 2024 May; 30(10):2260-2271. PubMed ID: 38488807
[TBL] [Abstract][Full Text] [Related]
17. Genetic variants and copy number changes in soft tissue leiomyosarcoma detected by targeted amplicon sequencing.
Rao U; Schoedel KE; Petrosko P; Sakai N; LaFramboise W
J Clin Pathol; 2019 Dec; 72(12):810-816. PubMed ID: 31300531
[TBL] [Abstract][Full Text] [Related]
18. High-grade sarcoma diagnosis and prognosis: Biomarker discovery by mass spectrometry imaging.
Lou S; Balluff B; de Graaff MA; Cleven AH; Briaire-de Bruijn I; Bovée JV; McDonnell LA
Proteomics; 2016 Jun; 16(11-12):1802-13. PubMed ID: 27174013
[TBL] [Abstract][Full Text] [Related]
19. Integrated histologic and molecular analysis of uterine leiomyosarcoma and 2 benign variants with nuclear atypia.
Gao T; Finkelman BS; Ban Y; Li Y; Yin P; Bulun SE; Lu X; Ha C; Wei JJ
Cancer Sci; 2021 May; 112(5):2046-2059. PubMed ID: 33338329
[TBL] [Abstract][Full Text] [Related]
20. Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma.
Tsuyoshi H; Yoshida Y
Cancer Sci; 2018 Jun; 109(6):1743-1752. PubMed ID: 29660202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
